These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 3456271)

  • 21. Sequential administration of epirubicin and paclitaxel for advanced breast cancer. A phase I randomised trial.
    Focan C; Graas MP; Beauduin M; Canon JL; Salmon JP; Jerusalem G; Focan-Henrard D; Lobelle JP; Schallier D
    Anticancer Res; 2005; 25(2B):1211-7. PubMed ID: 15865068
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A dose-finding study of epirubicin in combination with paclitaxel in the treatment of advanced breast cancer.
    Conte PF; Michelotti A; Baldini E; Salvadori B; Gennari A; Da Prato M; Tibaldi C; Salzano E; Gentile A
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):28-31. PubMed ID: 8893896
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A new six-drug antiblastic regimen (R 14) at low doses (micropolychemotherapy) compared to CMF in the treatment of metastatic breast cancer: phase III study.
    Pannuti F; Iafelice G; Martoni A; Fruet F; Angelelli B; Casadei M
    Chemioterapia; 1984 Aug; 3(4):216-9. PubMed ID: 6398121
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activity and safety of epirubicin plus paclitaxel in advanced breast cancer.
    Conte PF; Michelotti A; Baldini E; Tibaldi C; DaPrato M; Salvadori B; Giannessi PG; Gentile A; Biadi O; Mariani M
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):28-32. PubMed ID: 8629033
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
    Hainsworth JD; Jolivet J; Birch R; Hopkins LG; Greco FA
    Cancer; 1997 Feb; 79(4):740-8. PubMed ID: 9024712
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Weekly epirubicin versus doxorubicin as second line therapy in advanced breast cancer. A randomized clinical trial.
    Gasparini G; Dal Fior S; Panizzoni GA; Favretto S; Pozza F
    Am J Clin Oncol; 1991 Feb; 14(1):38-44. PubMed ID: 1987737
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preliminary results of a phase II study of epirubicin and paclitaxel as first-line treatment in patients with metastatic breast cancer.
    Lück HJ; Thomssen C; du Bois A; Lisboa BW; Untch M; Kühnle H; Jänicke F; Meerpohl HG; Lindner C; Konecny G; Hecker D; Diergarten K
    Semin Oncol; 1997 Feb; 24(1 Suppl 3):S13-6. PubMed ID: 9071334
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of different neoadjuvant chemotherapy regimens on locally advanced breast cancer.
    Coskun U; Gunel N; Onuk E; Yilmaz E; Bayram O; Yamac D; Cihan A; Ucan B; Yildirim Y; Celenkoglu G; Ozkan S
    Neoplasma; 2003; 50(3):210-6. PubMed ID: 12937855
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I-II study of epirubicin in multiple myeloma.
    Case DC; Ervin TJ; Gams R; Sonneborn HL; Paul SD; Oldham FB
    Cancer Res; 1988 Nov; 48(21):6246-8. PubMed ID: 3167870
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer.
    Jain KK; Casper ES; Geller NL; Hakes TB; Kaufman RJ; Currie V; Schwartz W; Cassidy C; Petroni GR; Young CW
    J Clin Oncol; 1985 Jun; 3(6):818-26. PubMed ID: 3859587
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [A phase II study of epirubicin in advanced lung cancer].
    Furuse K; Fukuoka M; Yamamoto M; Kawahara M; Tsuruta M; Kodama N; Arai R; Hayashi S; Kiyota M; Kubota K
    Gan To Kagaku Ryoho; 1986 Sep; 13(9):2835-40. PubMed ID: 3019252
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New anthracycline analogs in advanced breast cancer.
    Bonfante V; Ferrari L; Brambilla C; Rossi A; Villani F; Crippa F; Valagussa P; Bonadonna G
    Eur J Cancer Clin Oncol; 1986 Nov; 22(11):1379-85. PubMed ID: 3470179
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized phase II trial of rubidazone and adriamycin in women with advanced breast cancer.
    Ingle JN; Ahmann DL; O'Fallon JR; Bisel HF; Rubin J; Kvols LK; Giuliani ER
    Cancer Treat Rep; 1979; 63(11-12):1701-5. PubMed ID: 526908
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epirubicin, alone or in combination chemotherapy, for metastatic breast cancer. Provincial Breast Cancer Disease Site Group and the Provincial Systemic Treatment Disease Site Group.
    Findlay BP; Walker-Dilks C
    Cancer Prev Control; 1998 Jun; 2(3):140-6. PubMed ID: 10093625
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I study of epirubicin given on a weekly schedule.
    Snyder R; Bishop J; Brodie G; Burns W; Coates A; Levi J; Raghavan D; Schwarz M; Tattersall M; Thomson D
    Cancer Treat Rep; 1987 Mar; 71(3):273-6. PubMed ID: 3028619
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer.
    Perez DJ; Harvey VJ; Robinson BA; Atkinson CH; Dady PJ; Kirk AR; Evans BD; Chapman PJ
    J Clin Oncol; 1991 Dec; 9(12):2148-52. PubMed ID: 1960557
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized phase II trial of carminomycin versus 4'-epidoxorubicin in advanced breast cancer.
    Rozencweig M; ten Bokkel Huinink W; Cavalli F; Bruntsch U; Dombernowsky P; Høst H; Bramwell V; Renard G; Van Glabbeke M; Decoster G
    J Clin Oncol; 1984 Apr; 2(4):275-81. PubMed ID: 6584561
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Comparative study of adriamycin, epirubicin and mitoxantrone in cancer of the breast. Review of the literature].
    Delozier T; Vernhes JC
    Bull Cancer; 1991 Nov; 78(11):1013-25. PubMed ID: 1369547
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-dose epirubicin as primary chemotherapy in advanced breast carcinoma: a phase II study.
    Carmo-Pereira J; Costa FO; Miles DW; Henriques E; Richards MA; Rubens RD
    Cancer Chemother Pharmacol; 1991; 27(5):394-6. PubMed ID: 1999000
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antitumor activity of liposome-encapsulated doxorubicin in advanced breast cancer: phase II study.
    Treat J; Greenspan A; Forst D; Sanchez JA; Ferrans VJ; Potkul LA; Woolley PV; Rahman A
    J Natl Cancer Inst; 1990 Nov; 82(21):1706-10. PubMed ID: 2231759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.